glp-1 bulimia Receptor Agonists and Research to Treat Overeating and Substance Use Disorders GLP-1 Medications and Eating Disorders
Description
In the phase 2b trial, however, the reductions in glycated hemoglobin and body weight in participants treated with NNC0090-2746 were similar to those in the group treated with liraglutide (76), and no phase 3 trial of NNC0090-2746 has been reported yet
Trapp and Cork, 2015)
View at Publisher | View at Google Scholar Singh AK et al
These interactions deserve attention from both you and your healthcare provider
BlueWater is your partner for comprehensive wellnessnot just weight loss, but looking and feeling your absolute best at every stage of life
